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Abstract The development of an impulse control disor-
der (ICD) is now recognized as a potential nonmotor
adverse effect of dopamine replacement therapy in Par-
kinson’s disease (PD). Here, recent epidemiological,
neurophysiological and genetic advances are summarized
to outline potential mechanisms involved. It is safe to say
that dopaminergic drugs, particularly dopamine agonists,
are able to induce ICDs only in a minority of patients,
while the majority are somehow protected from this
adverse effect. While it seems clear that men with early-
onset PD are more vulnerable, other predisposing factors,
such as various current or pre-PD personality traits, are a
matter of debate. In terms of neurophysiological advances,
one may ﬁnd striking analogies to the addiction literature
suggesting a causal chain beginning with certain pre-
disposing conditions of striatal dopamine synapses, an
‘‘unnatural’’ increase of dopamine stimulation and a char-
acteristic pattern of resulting functional changes in remote
networks of appetitive drive and impulse control. Future
prospects include potential add-on medications and the
possible identiﬁcation of genetic predispositions at a gen-
ome-wide scale. Functional imaging of pharmacogenetic
interactions (imaging pharmacogenomics) may be an
important tool on that road.
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Introduction
Impulse control disorders (ICDs), such as pathological
gambling, compulsive shopping, binge eating and hyper-
sexuality may develop as nonmotor adverse effects of
dopamine replacement therapy in patients with Parkinson’s
disease (PD) (Driver-Dunckley et al. 2003; Seedat et al.
2000). In this review, we aim to summarize promising
recent advances in characterizing (1) circumstances under
which these behavioral disturbances appear, (2) neurobio-
logical trigger mechanisms that may be involved and (3)
possible neurophysiologic and genetic makeups that may
help explain why some individuals are more vulnerable
than others. For the sake of focus, certain types of impul-
sive and repetitive behavior that are observed in PD will
not be discussed in this review. While there is growing
evidence that electric stimulation of the subthalamic
nucleus blocks the so-called ‘hyperdirect’ pathway of the
basal ganglia, which may in turn produce a certain type of
impulsivity (Frank et al. 2007), the exact relationship
between subthalamic stimulation in PD and ICDs is
unclear, as these abnormal behaviors may either follow
neurostimulation (Lim et al. 2009; Volkmann et al. 2010)
or resolve after dopaminergic dose reduction associated
with successful surgery (Ardouin et al. 2006; Bandini et al.
2007; Witjas et al. 2005). It is therefore conceivable that
subthalamic stimulation and dopaminergic medication may
both lead to impulsivity, yet by different neurobiological
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anti-Parkinsonian drug use––commonly referred to as
dopamine dysregulation syndrome (DDS)––is sometimes
associated with the development of ICDs in PD, epidemi-
ological ﬁndings regarding DDS are markedly different
from ICDs insofar as DDS usually develops as a compli-
cation of long-term dopaminergic therapy in advanced PD
(O’Sullivan et al. 2009). Sometimes associated with DDS
are repetitive, complex stereotyped behaviors (e.g., col-
lectionism), described as punding (Evans et al. 2004). Even
though punding certainly has elements of compulsions, it is
felt to lie outside of the ICD spectrum (Evans et al. 2009).
Clinical observations
Epidemiology of ICDs in PD
A recent blinded, multi-center cross-sectional study with
over 3,000 patients in North America constitutes the
strongest effort yet to gather scientiﬁc evidence about the
circumstances, in which ICDs in PD may occur (Weintraub
et al. 2010). Similar to epidemiological studies in other PD
populations (Lee et al. 2010), one or more forms of ICD
was found in 13.6% of medicated PD patients. Moreover,
the risk to develop an ICD appeared to increase threefold
when dopamine agonists (DAAs) were part of the thera-
peutic regimes. This ﬁnding was independent of the type of
DAA used, but combinational use with levodopa was found
to be a contributing factor. Interestingly, ICDs have also
been identiﬁed with similar or even higher frequencies in
other DAA-treated conditions such as restless-legs syn-
drome, prolactinoma or ﬁbromyalgia (Cornelius et al.
2010; Grosset et al. 2007; Holman 2009). Although this
certainly is a strong indication for a speciﬁc pharmaco-
logical trigger mechanism of DAAs, it has to be noted that
the prevalence of ICDs in PD patients on dopaminergic
medication excluding DAAs was still found to be much
higher than in the general population (Crockford et al.
2008). One of the most interesting ﬁndings of this cross-
sectional study was the absence of a signiﬁcant dose rela-
tionship for DAAs, despite the fact that in the individual
patient with a DAA-induced ICD, a dose threshold does
sometimes feel quite palpable (Weintraub et al. 2010). Of
note, a different epidemiological study showed that such a
dose relationship may indeed be found, when clinical
parameters including risk factors (see below) are taken into
account (Lee et al. 2010). This indicates that the devel-
opment of ICDs may stem from an interaction of a speciﬁc
pharmacological trigger with intrinsic neurobiological
vulnerability factors.
Apart from unusual manifestations of ICDs (Bienfait
et al. 2010; Bonfanti and Gatto 2010; Odiyoor et al. 2009;
Pinggera et al. 2009), pathological gambling, compulsive
shopping, binge eating and hypersexuality seem to be
equally common in DAA-medicated PD (Fig. 1). However,
men seem to be more prone to develop pathological gam-
bling or hypersexuality, while women have higher rates of
compulsive shopping and binge eating. It is yet unclear
how much of these differences may stem from differences
in the mesocorticolimbic reward system (Hoeft et al. 2008;
Munro et al. 2006) or reporting biases due to social
acceptance.
Factors of individual predisposition
Male gender, early-onset PD, current or pre-PD personality
traits characterized by high impulsivity and novelty-seek-
ing personality traits, family or personal history of ICD
symptoms or substance abuse (including current smoking)
may all be regarded as considerable risk factors (Weintraub
et al. 2010). The mechanisms of male preponderance are
unclear, but imaging studies comparing men with women
after exposure to rewarding stimuli have shown higher
release of dopamine in the ventral striatum (Munro et al.
2006) and increased activation of the mesocorticolimbic
system in men (Hoeft et al. 2008). Compared to the general
population, a previous history of ICDs or substance abuse
is less frequent in PD patients developing ICDs after the
initiation of dopamine replacement therapy (Gallagher
et al. 2007). More recently, the akinetic-rigid phenotype
has been suggested to be more prone to impulsive
responses and risk taking than tremor-dominant phenotype
(Singh-Curry et al. 2010). An increased prevalence of
executive dysfunctions in PD patients with ICD behaviors
Fig. 1 Prevalence of the most frequent impulse control disorders
(ICDs) in PD patients on dopamine agonists (DAA) according to the
DOMINION study (Weintraub et al. 2010). From left to right:
compulsive shopping, pathological gambling, binge eating and
hypersexuality
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123is controversial, as found in the study of Santangelo et al.
(Santangelo et al. 2009), while no differences in frontal
lobe functions between gamblers versus non-gamblers have
been reported in other studies (Siri et al. 2010; Voon et al.
2007). Further studies are needed to assess cognitive pro-
ﬁles of large samples of PD patients with and without
ICDs, particularly focusing on frontal lobe functions while
reliably eliminating potential biases such as age
differences.
In the non-parkinsonian population, there seems to be a
close association between individual vulnerability to risk-
taking behaviors and genetically determined variants in
different neurotransmitter systems, mainly the dopaminer-
gic mesocorticolimbic circuit (Brewer and Potenza 2008;
Forbes et al. 2009; Haile et al. 2007). The mesolimbic
dopaminergic transmission is centrally involved in the
motivational salience of stimuli and appetitive or reward-
dependent behaviors (Berridge and Robinson 2003). In
particular, distinct differences in magnitude and pattern of
dopamine release in the ventral striatum have been linked
to disorders involving enhanced reward seeking, such as
addiction and ICDs (Hyman et al. 2006).
In Table 1, we provide an overview of genetic ﬁndings
in non-parkinsonian individuals with ICDs, focusing on
dopamine transmission but not without taking a glance at
other neurotransmitter systems.
Neurobiological hypotheses in the non-parkinsonian
population
In the last few years, ICDs such as pathological gambling
have been increasingly regarded as a ‘behavioral addiction’
(Goudriaan et al. 2004; Potenza 2008; Tamminga and Nes-
tler 2006). Many of the diagnostic criteria for ICDs share
featureswiththoseforsubstanceusedisorders,underscoring
its classiﬁcation as ‘behavioral addiction’ in the ﬁfth edition
oftheDiagnosticandStatisticalManualofMentalDisorders
(DSM, American Psychiatric Association, 1994). The main
features of substance use disorders include: (a) enhanced
salience attribution to drug-related stimuli in comparison to
other natural rewards, (b) failure to inhibit the urge to obtain
the drug, (c) withdrawal symptoms including cue-induced
craving and (d) continued engagement in maladaptive risk-
Table 1 Genes involved in impulse control disorders, substance addiction and associated traits in PD and non-PD populations
Transmitter
system
Protein Gene/allele Population ICDs/addiction References
Dopamine DAT SLCA3 Non-PD ICDs (BE, HS), substance abuse,
reward sensitivity and
impulsivity
Muramatsu and Higuchi 1995; Shinohara
et al. 2004; Kreek et al. 2005; Guo et al.
2007; Forbes
et al. 2009; Hahn et al. 2010
DRD1 800 T/C Non-PD ICDs (PG), substance abuse Comings et al. 1997; da Silva et al. 2007
DRD2/
ANKK1
TaqlA Non-PD ICDs (PG, BE), alcohol and
nicotine abuse
Blum et al. 1995; Comings et al. 1996;
Neville et al. 2004; Gelernter et al. 2006;
Yang et al. 2007; Haile et al. 2007
DRD3 p-S9G Non-PD,
PD
ICDs, alcohol abuse and risk
taking
Kreek et al. 2005; Lee et al. 2009
DRD4 Exon III;
7-repeat
allele
Non-PD ICDs (PG, BE), substance abuse
and novelty seeking
Perez de Castro et al. 1997; Gelernter et al.
1997; Comings et al. 1999; Levitan et al.
2004; Rogers et al. 2004; Eisenegger 2010
Catecholaminergic COMT Val158Met Non-PD ICDs (BE), substance abuse and
reward sensitivity
Kreek et al. 2005; Hersrud et al. 2009;
Lohoff et al. 2008; Dreher et al. 2009
MAD-A Promoter:
3-repeat
allete
Non-PD ICDs (PG) Ibanez et al. 2000; Petez de Castro et al. 2002
Serotonergic Serotonin
transporter
SLC6A4 Non-PD ICDs (PG, CS, TM), substance
abuse
Perez de Castro et al. 1999 and 2002; Devor
et al. 1999; Hemmings et al. 2006
Tryptophan
hydroxylase
TPH1 Non-PD ICDs (PG), substance abuse Comings et al. 2001; Kreek et al. 2005;
Nielsen et al. 2008
Glutamatergic NMDA
receptor 2B
GRIN2B Non-PD,
PD
ICDs, alcohol abuse Kim et al. 2006; Lee et al. 2009
Opioid l/K receptors OPRM1;
OPRK1
Non-PD Substance abuse, impulsivity Kreek et al. 2005; Olmstead et al. 2009
ANKK1 ankyrin repeat and kinase domain containing-1 gene, BE binge eating, CS compulsive shopping, COMT catechol-O-methyl-transferase,
DAT dopamine transporter, DRD dopamine receptor gene, HS hypersexuality, ICDs impulse control disorders, MAO-A monoamine oxidase A,
NMDA N-methyl-D-aspartate, PG pathological gambling, SERT serotonin transporter, TM trichotillomania
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123taking behaviors despite negative future consequences
(Goldstein and Volkow 2002; Kalivas and Volkow 2005).
Several of these common features are modulated by dopa-
mine and are therefore of great interest, as they may con-
stitute possible mediators of ICDs in subjects chronically
treatedwithdopaminergicdrugsandwillthusbereviewedin
the following paragraphs.
Although we focus on dopamine, other neurotransmitters
(e.g., serotonin and opioids) may also be involved in the
development of impulse control and addictive disorders.
Serotoninergic neurons project form the raphe nucleus to
mesocorticolimbic areas including prefrontal/orbitofrontal
cortex, amygdala and hippocampus and are known to modu-
late delay discounting and reversal learning (Clarke et al.
2004;R o g e r s2011). Moreover, forebrain serotonin levels
were found to be negatively correlated with measures of
impulsivity (Brewer and Potenza 2008) and risk-taking
behavior (Potenza 2001;M o r e n oe ta l .2010). The mu-opioid
system is activated in response to gambling behavior
(Shinohara et al. 2004) and is involved in the processing of
hedonic responses and incentive motivation by modulating
thenucleusaccumbensandtheventralglobuspallidum,either
directly (Smith et al. 2009) or indirectly, via gamma-amino-
butyric acid input to the mesolimbic dopamine pathway
(Ikemotoetal.1997; Grantetal.2003; Olmstead et al. 2009).
DA-mediated mechanisms leading to (drug-related
and behavioral) addiction
Exposure to rewards, including drugs of abuse and
behaviors (such as gambling, sex or eating), induce phasic
dopamine release from the ventral tegmental area into the
nucleus accumbens, a process that is associated with
reinforcement effects underlying stimulus–response con-
ditioned learning and amplify salience attribution to the
speciﬁc reward (Volkow et al. 2008). Repeated exposure to
the reward––drug or behavior––may result in over-activa-
tion of the reward and motivational circuits (including the
medial orbitofrontal cortex, OFC) while decreasing
the top–down control of inhibitory cortical areas (including
the ACC) (Potenza 2008). Pathologically increased sal-
iency attribution to a particular reward produces an irre-
sistibleandincreasinglycompulsivedrivetowardthatreward
andawayfromotherreinforcers,ﬁnallyleadingtowithdrawal
symptoms and craving, similar to substance use disorders
(Hyman 2005; Robinson and Berridge 1993) and which has
been hypothesized to be mediated by changes in dopamine
and glutamate functioning (Kalivas and Volkow 2005).
Personality, behavior and cognition
The role of personality measures in the development of
ICDs, such as sensation seeking and extraversion, is still
controversial (Brand et al. 2005; Goudriaan et al. 2009;
Jimenez-Murcia et al. 2010; Leiserson and Pihl 2007).
Cognitive functions in non-parkinsonian subjects with PG
demonstrated reduced decision-making abilities and exec-
utive dysfunction compared to controls (Alessi and Petry
2003; Brand et al. 2005; Forbush et al. 2008; Goudriaan
et al. 2005; Kalechstein et al. 2007; Labudda et al. 2007;
Lakey et al. 2006; Marazziti et al. 2008). In particular, non-
parkinsonian gamblers show enhanced impulsivity together
with impaired cognitive ﬂexibility with higher rates of
perseveration and impaired response inhibition. This is in
consistence with studies in substance abuse (Forbush et al.
2008; Goudriaan et al. 2004; Kalechstein et al. 2007;
Kertzman et al. 2008). Notably, decision-making impair-
ment in pathological gamblers mainly includes reduced
response shifting after losses (Goudriaan et al. 2006),
supporting the hypothesis of impaired sensitivity to nega-
tive reinforcers and thus affecting the so-called ‘win–stay–
lose–shift’ heuristic.
Neuroimaging ﬁndings
Studies using functional neuroimaging in healthy subjects
demonstrated that rewarding events increase activity in the
medial OFC, amygdala and ventral striatum (Hampton
et al. 2007; Knutson and Cooper 2005; Yacubian et al.
2006), while increased brain activity in the ventrolateral
prefrontal cortex (vlPFC), ACC and ventral striatum is
generally associated with decision making under risk
(Hewig et al. 2009; Hollander et al. 2005; Rao et al. 2008;
Tom et al. 2007).
Resting state brain metabolism of pathological gamblers
was found to be higher than matched controls in the medial
OFC and other medial prefrontal cortical areas (Hollander
et al. 2008). Similarly, in subjects with Internet game
overuse, increased glucose metabolism in the medial OFC,
the caudate and the insula was associated with greater
impulsiveness compared to controls (Park et al. 2010).
Reduced activation of the ventral striatum and the ventral
prefrontal cortex during non-speciﬁc rewarding and pun-
ishing events has been shown in non-parkinsonian patho-
logical gamblers, subjects with eating disorders and drug
abusers compared to normal controls (de Ruiter et al. 2009;
Potenza 2008; Reuter et al. 2005), suggesting a blunted
response to rewards as well as to losses. On the other hand,
also in pathological gamblers, lower vlPFC activity was
found during monetary loss (de Ruiter et al. 2009), which is
consistent with a diminished sensitivity to negative rein-
forcers (Goudriaan et al. 2005).
To say it in one grossly simpliﬁed sentence: neuroim-
aging evidence in the non-parkinsonian population points
toward a reduced engagement of brain areas involved in the
prevention of negative outcomes via inhibitory circuits
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123(e.g., vlPFC) and an ampliﬁed engagement of areas
mediating goal-directed behavior via motivational circuits
(e.g., medial OFC).
Possible pathophysiologic pathways fostering ICDs
in PD
Dopaminergic depletion in PD involves not only the
nigrostriatal ‘motor’ loop, but also, though to a lesser
degree, the mesocorticolimbic circuit, affecting the nucleus
accumbens, OFC, ACC, amygdala and the hippocampus
(Kish et al. 1988; Ouchi et al. 1999). All these regions are
critically involved in the modulation of behavior in posi-
tive/negative reinforcement learning, motivation, inhibitory
control and decision making (Frank et al. 2004; Schultz
2002; Tremblay and Schultz 1999). Thus, it is tempting to
think that these brain regions must be––in one way or
another––implicated in the development of ICDs. More-
over, the fact that in PD, mesocortical and mesolimbic
circuitries are relatively intact, yet may undergo the same
pharmacologic effect of dopaminergic treatment than the
motor loop has led to the intuitive proposition of an
‘overdosing’ of the mesolimbic dopaminergic system
(Cools and Robbins 2004). This mental concept is analo-
gous to the ‘overdose theory’ of the frontal lobes, which we
may ascribe to C. David Marsden’s mastermind (Gotham
et al. 1988). Note, however, that only a minority of PD
patients on dopaminergic medication actually develop
ICDs. Therefore, this concept––however intuitively con-
vincing––does not give a sufﬁcient answer to the most
crucial questions associated with DAA-induced ICDs in
PD: how do dopaminergic drugs generally alter limbic brain
functions? What is different in the brain of susceptible PD
patients? And what exactly happens in their brain that does
not happen in the majority of PD patients? Recent imaging
studies have begun to shed some light on those questions.
General drug-mediated changes in reward processing
and reinforcement learning
Several lines of evidence point toward a reduced sensitivity
of the reward system as a key feature in drug addiction and
pathological gambling in the non-parkinsonian population
(Goldstein et al. 2007; Potenza 2008; Reuter et al. 2005). In
line with this notion, Riba et al. found that DAA leads to
blunted neuronal responses to unexpected ﬁnancial wins in
the ventral striatum of healthy subjects (Riba et al. 2008).
Extending this result to PD patients and comparing DAA
and levodopa medication effects, van Eimeren et al. found
that both medications reduced reward sensitivity in the
ventral striatum, but only DAA greatly diminished reward
sensitivity in the OFC (van Eimeren et al. 2009).
Moreover, there is ample evidence that DAAs disrupt
appropriate feedback from negative outcomes in rein-
forcement learning. Behaviorally, PD patients are less able
to learn from negative feedback when medicated with DAA
(Bodi et al. 2009; Cools et al. 2006; Frank et al. 2004).
Neurophysiologically, DAAs seem to prevent decreases in
DA transmission that occur with negative feedback (van
Eimeren et al. 2009). Indeed, abnormalities found in reward
and punishment sensitivity could generally result in aber-
rant expectations of reward and loss and, consequently, to a
pathological ‘over-optimism’, contributing to the continu-
ation of behaviors such as pathological gambling. Yet, more
studies are deﬁnitely needed to disentangle general (all
patients) from speciﬁc (only vulnerable patients) DAA
effects on reward and reinforcement learning.
Characteristic features of dopaminergic mesolimbic
synapses
In a recent [11C]-raclopride PET study, (Steeves et al.
2009) compared levels of D2-receptor availability in PD
patients with and without DAA-induced ICD behavior.
Reduced availability of striatal D2-receptors was found to
be a distinctive feature of the vulnerable patient group.
This result is well in accordance with equivalent ﬁndings in
drug addiction, in which decreased D2 receptor availability
in combination with impaired OFC and ACC metabolism
has been found (Volkow et al. 2001). A reduction in D2
receptor availability possibly constitutes a vulnerability
that is genetically determined (see Table 1). In healthy
volunteers, this genetically driven reduction in D2-recep-
tors leads to impaired recruitment of the ACC and the right
lateral OFC in negative feedback learning (Jocham et al.
2009). Note that reduced D2-receptor availability––as
measured by [11C]-raclopride PET––can have three pos-
sible origins: reduced density of post-synaptic D2-recep-
tors, increased levels of synaptic dopamine or both. In this
respect, it is important to take into account another recent
study measuring striatal dopamine transporter density with
single photon emission tomography (Cilia et al. 2010). PD
patients with DAA-induced ICD––as compared to patients
without—demonstrated reduced levels of dopamine trans-
porters speciﬁcally in the ventral striatum. Dopamine
transporters are the single most important way to eliminate
dopamine from the synaptic cleft. Therefore, it is tempting
to infer increased levels of synaptic dopamine in vulnerable
PD patients, which could also help explain the ﬁnding of
reduced D2-receptor availability.
Characteristic patterns of neuronal activity
Similar to ﬁndings in the non-PD population (see
‘‘Neurobiological hypotheses in the non-parkinsonian
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123population’’), ICDs in PD patients seem to be associated
with functional changes in circuitries that evaluate or
mediate rewarding outcomes and/or evaluate risks during
decision making. During rest and on regular dopaminergic
medication, PD patients with active ICD behavior showed
relatively increased blood ﬂow in the OFC, the amygdala
and globus pallidum indicative of a relative overactivity of
those areas in an ‘‘idle’’ state (i.e., without engagement in a
speciﬁc task) (Cilia et al. 2008). A recent fMRI study
focused on the ventral striatum as a region of interest and
found decreased resting blood ﬂow together with reduced
modulation of activity during risk taking in the ventral
striatum of medicated PD patients with active ICDs (Rao
et al. 2010). Another fMRI study investigated DAA-
induced changes during a feedback learning task (Voon
et al. 2010). In the ventral striatum, DAA medication
speciﬁcally induced increased activation in relation to
expected gains, while DAA medication diminished reac-
tivity associated with expected losses in PD patients with
active ICDs (Voon et al. 2010). Although these results may
generally underscore the involvement of reward processing
areas, the interpretation of activation data in this study is
complicated by the fact that DAA medication also differ-
entially modulated task performance in patients with and
without ICD behavior. Investigating DAA-induced changes
in regional brain activity during a card selection game with
predetermined probabilistic outcomes, another recent
imaging study found that only in vulnerable PD patients,
DAA medication led to a deactivation of areas implicated
in response inhibition and impulse control (vlPFC, ACC,
amygdala, internal globus pallidus) (van Eimeren et al.
2010). It is interesting to note that most of the participants
of this study were previously investigated with [11C]-
raclopride PET and showed reduced availability of striatal
D2-receptors (Steeves et al. 2009). In good accordance
with a differential modulation of corticostriatal inhibitory
networks, a functional disconnection has been recently
found between the ACC and the striatum in PD patients
with ICDs (Cilia et al. 2011). This disconnection may be
involved in the failure of loss-related behavioral shifts due
to an inability to disengage from reward-seeking behaviors
that previously gained abnormal salience via dopamine-
mediated positive reinforcements (Baler and Volkow
2006). Future neuroimaging studies in PD patients may
help to conﬁrm and extend these hypotheses by speciﬁcally
focusing on differential and potential additive effects of
various types of DAA and levodopa (Dewey 2010). Taking
all available ﬁndings together, however, we may observe a
striking analogy to the existing addiction literature that
suggest a causal chain beginning with certain predisposing
conditions of striatal dopamine synapses, an ‘‘unnatural’’
increase of dopamine stimulation and a characteristic pat-
tern of resulting functional changes in remote networks of
appetitive drive and impulse control (Potenza 2008; Vol-
kow et al. 2001).
The Yin and Yang of appetitive drive and inhibitory
control: attempt of a uniﬁed hypothesis
As mentioned before, DAA may increase appetitive drive
(novelty seeking and impulsivity) while hampering nega-
tive feedback learning and behavioral inhibition. However,
only a minority of PD patients actually develop ICD
behaviors, suggesting an individual predisposition. One can
only speculate on the underlying pharmacophysiologic–
psychological interactions that drive behavioral change in
susceptible patients. On the assumption of a relatively
increased synaptic dopamine level in the striatum of vul-
nerable PD patients, we derive hypotheses based and an
established model of the effects of tonic and phasic dopa-
mine release on cortical connections with the direct and
indirect pathways of the basal ganglia (Fig 2a). Decision
making is believed to involve interactions of inhibitory and
motivational inputs to the ventral striatum that are modiﬁed
by convergent dopaminergic innervation from the ventral
tegmental area (Goto et al. 2007). Phasic dopamine release,
via D1 receptor activation, has been shown to facilitate
inputs from motivational areas (e.g., medial OFC, fronto-
polar cortex) and thereby strengthens the inﬂuence of the
direct or ‘Go’ pathway on executive areas (Goto and Grace
2005). Conversely, a transient reduction of tonic dopamine
release, via D2-receptor inactivation, increases inputs from
inhibitory areas (e.g., vlPFC and ACC) and thereby
strengthens the inﬂuence of the indirect or ‘NoGo’ pathway
on areas of executive control (Goto and Grace 2005).
Dopaminergic depletion in the ventral striatum of PD
patients regularly decreases tonic D2-receptor stimulation.
In susceptible patients on the other hand, a constitutionally
increased tonic dopamine level would lead to a relatively
normal level of tonic D2-receptor stimulation in the ventral
striatum. According to the above-mentioned model, thera-
peutic use of DAA would further increase D2-receptor
stimulation to the point of an ‘‘overdose’’ situation, leading
to a hampered engagement of inhibitory cortical areas and
increased inﬂuence of appetitive drive areas (Fig. 2b). This
model would be in good accordance with ﬁndings in vul-
nerable PD patients, who showed reduced involvement of
vlPFC and ACC and increased resting activity of the
medial OFC in association with an increased tonic D2-
receptor stimulation (Cilia et al. 2008, 2010, 2011; Steeves
et al. 2009; van Eimeren et al. 2010). While this hypothesis
may be intuitively convincing, it will have to be tested in
further studies involving genetic, behavioral and neuro-
imaging methods.
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123Future directions in pharmacology, imaging
and genomics
The management options of ICDs in PD are not entirely
satisfactory. While there are no evidence-based treatment
strategies available, the most common form of therapeutic
intervention in DA-induced ICDs in PD is the tapering and
substitution of DAA (Galpern and Stacy 2007). It might be
worth trying another type of DAA, if the clinical effect of
DAA is otherwise deemed superior to alternatives. More-
over, the notion of the so-called DAA withdrawal syn-
drome (DAWS)––deﬁned as psychological (e.g., anxiety,
panic attacks, depression) or physical (e.g., diaphoresis,
orthostatic hypotension) symptoms caused by the tapering
of DAAs (Rabinak and Nirenberg 2010; Schlesinger et al.
2010)––underscores an urgent need for more therapeutic
options for the clinician. Although case reports suggest
possible roles for subthalamic stimulation (Bandini et al.
2007; Halbig et al. 2009) (but see Moro 2009), enteral
carbidopa/levodopa infusions, amantadine, zonisamide,
carbamazepine or clozapine (Bach et al. 2009; Bermejo
et al. 2010; Gerschlager and Bloem 2009; Rotondo et al.
2010; Thomas et al. 2010), none of these potential add-on
medications have been tested in prospective, randomized
controlled trials. It is also worth mentioning that SSRI
medications are commonly used in the treatment of non-
parkinsonian ICDs and that opioid antagonists also seem to
be effective (Leung and Cottler 2009), probably by
increasing punishment sensitivity (Petrovic et al. 2008).
Future neuroimaging studies may contribute to direct
attention to potential add-on medications by evaluating the
inﬂuence of certain drugs (e.g., amantadine) on motiva-
tional and inhibitory circuitries.
Moreover, a steady ﬂow of new neuroimaging studies
will continue to increase our understanding of dopami-
nergic modulation of human behavior. It will be important
to follow recent developments and to test hypotheses in
clinically realistic circumstances (dopaminergic medica-
tion in parkinsonian populations). While most neuroimag-
ing studies, for obvious reasons, will focus on the
dopaminergic system, it will also be important to illumi-
nate potentially crucial contributions of other neurotrans-
mitter systems (as discussed above).
In the non-parkinsonian population, genetic factors of
individual predisposition have been indentiﬁed (see
Table 1). In the next few years, we need to systematically
test genetic variances in large PD populations to poten-
tially describe genetic makeups that may predict socially
devastating side effects of anti-parkinsonian treatment.
What we need is a better understanding of genetic
determinants of pharmacologic effects on brain function.
Functional imaging of pharmacogenetic interactions
(imaging pharmacogenomics) will be an important tool to
this end.
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Fig. 2 The Yin-and-Yang model of appetitive drive and inhibitory
control. Left The effects of tonic and phasic dopamine release on
cortical connections with the direct and indirect pathways of the basal
ganglia (here nucleus accumbens (Nacc) and ventral tegmental area
(VTA), modiﬁed model after Goto and Grace 2005). Right In a
majority of the patients with PD, dopaminergic depletion decreases
tonic D2-receptor stimulation in the ventral striatum/Nacc. In
susceptible patients on the other hand, a constitutionally increased
tonic dopamine level leads to relatively normal levels of tonic D2-
receptor stimulation in the ventral striatum/Nacc. Therapeutic use of
DAA further increases D2-receptor stimulation to the point of an
‘‘overdose’’ situation, leading to a hampered engagement of inhibitory
cortical areas and increased inﬂuence of appetitive drive areas
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